These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 28059952)

  • 1. ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia.
    Burke AC; Huff MW
    Curr Opin Lipidol; 2017 Apr; 28(2):193-200. PubMed ID: 28059952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis.
    Burke AC; Telford DE; Huff MW
    Curr Opin Lipidol; 2019 Feb; 30(1):1-9. PubMed ID: 30586346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.
    Feng X; Zhang L; Xu S; Shen AZ
    Prog Lipid Res; 2020 Jan; 77():101006. PubMed ID: 31499095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in
    Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW
    Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):647-656. PubMed ID: 28153881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ETC-1002 (Bempedoic acid) for the management of hyperlipidemia: from preclinical studies to phase 3 trials.
    Ruscica M; Banach M; Sahebkar A; Corsini A; Sirtori CR
    Expert Opin Pharmacother; 2019 May; 20(7):791-803. PubMed ID: 30810432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
    Pinkosky SL; Newton RS; Day EA; Ford RJ; Lhotak S; Austin RC; Birch CM; Smith BK; Filippov S; Groot PHE; Steinberg GR; Lalwani ND
    Nat Commun; 2016 Nov; 7():13457. PubMed ID: 27892461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of ATP citrate lyase induces triglyceride accumulation with altered fatty acid composition in cancer cells.
    Migita T; Okabe S; Ikeda K; Igarashi S; Sugawara S; Tomida A; Soga T; Taguchi R; Seimiya H
    Int J Cancer; 2014 Jul; 135(1):37-47. PubMed ID: 24310723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine triphosphate citrate lyase: Emerging target in the treatment of dyslipidemia.
    Lemus HN; Mendivil CO
    J Clin Lipidol; 2015; 9(3):384-9. PubMed ID: 26073398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bempedoic acid: effect of ATP-citrate lyase inhibition on low-density lipoprotein cholesterol and other lipids.
    Paton DM
    Drugs Today (Barc); 2020 Sep; 56(9):573-582. PubMed ID: 33025951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The multifaceted therapeutic value of targeting ATP-citrate lyase in atherosclerosis.
    Verberk SGS; Kuiper KL; Lauterbach MA; Latz E; Van den Bossche J
    Trends Mol Med; 2021 Dec; 27(12):1095-1105. PubMed ID: 34635427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bempedoic Acid (ETC-1002): an Investigational Inhibitor of ATP Citrate Lyase.
    Bilen O; Ballantyne CM
    Curr Atheroscler Rep; 2016 Oct; 18(10):61. PubMed ID: 27663902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bempedoic Acid Unveils Therapeutic Potential in Non-Alcoholic Fatty Liver Disease: Suppression of the Hepatic PXR-SLC13A5/ACLY Signaling Axis.
    Sun Q; Guo Y; Hu W; Zhang M; Wang S; Lei Y; Meng H; Li N; Xu P; Li Z; Lin H; Huang F; Qiu Z
    Drug Metab Dispos; 2023 Dec; 51(12):1628-1641. PubMed ID: 37684055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia.
    Morrow MR; Batchuluun B; Wu J; Ahmadi E; Leroux JM; Mohammadi-Shemirani P; Desjardins EM; Wang Z; Tsakiridis EE; Lavoie DCT; Reihani A; Smith BK; Kwiecien JM; Lally JSV; Nero TL; Parker MW; Ask K; Scott JW; Jiang L; Paré G; Pinkosky SL; Steinberg GR
    Cell Metab; 2022 Jun; 34(6):919-936.e8. PubMed ID: 35675800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mendelian Randomization Study of
    Ference BA; Ray KK; Catapano AL; Ference TB; Burgess S; Neff DR; Oliver-Williams C; Wood AM; Butterworth AS; Di Angelantonio E; Danesh J; Kastelein JJP; Nicholls SJ
    N Engl J Med; 2019 Mar; 380(11):1033-1042. PubMed ID: 30865797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
    Granchi C
    Eur J Med Chem; 2018 Sep; 157():1276-1291. PubMed ID: 30195238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An allosteric mechanism for potent inhibition of human ATP-citrate lyase.
    Wei J; Leit S; Kuai J; Therrien E; Rafi S; Harwood HJ; DeLaBarre B; Tong L
    Nature; 2019 Apr; 568(7753):566-570. PubMed ID: 30944472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease.
    Guo L; Guo YY; Li BY; Peng WQ; Chang XX; Gao X; Tang QQ
    J Biol Chem; 2019 Aug; 294(31):11805-11816. PubMed ID: 31197036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ATP-citrate lyase: a key player in cancer metabolism.
    Zaidi N; Swinnen JV; Smans K
    Cancer Res; 2012 Aug; 72(15):3709-14. PubMed ID: 22787121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ATP citrate lyase (ACLY): a promising target for cancer prevention and treatment.
    Khwairakpam AD; Shyamananda MS; Sailo BL; Rathnakaram SR; Padmavathi G; Kotoky J; Kunnumakkara AB
    Curr Drug Targets; 2015; 16(2):156-63. PubMed ID: 25537655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.